The startup develops preventive treatments that enhance the natural immunity of fish, utilizing immunostimulants to improve resistance against bacterial pathogens and diseases. This approach replaces antibiotics, leading to higher survival rates and growth in aquaculture while providing cost-effective and sustainable solutions for fish cultivators.
Funding
$520K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OIFounders
Product
Problem
Bacterial infections in aquaculture lead to significant losses, with 40% of fish dying before harvest, resulting in approximately $6 billion in annual losses for the industry. The overuse of antibiotics in fish farming to combat these infections contributes to the rise of antibiotic-resistant bacteria, posing a threat to both animal and human health. Current disease management solutions often lack cost-effectiveness and sustainability.
Solution
AQUIT develops biotechnological solutions that serve as preventive treatments for infections in fish, offering an alternative to antibiotics. The core technology involves reproducing a key protein that enhances the natural immunity of fish, improving survival rates and overall health. This approach avoids the harmful inflammatory processes associated with traditional treatments and eliminates the need for withdrawal periods. A bioinformatic and AI platform is under development to identify proteins for key physiological processes in different species, expanding the platform's capabilities and contributing to a "One Health" approach.
Target Audience
The primary target audience includes fish cultivators and aquaculture farms seeking to reduce reliance on antibiotics, improve fish survival rates, and implement sustainable disease management practices.
Features
- Reproduction of a key protein to boost natural immunity in fish.
- Protection against major fish pathogens.
- No withdrawal period required after treatment.
- Reduced inflammatory response compared to traditional treatments.
- Bioinformatic and AI platform for identifying proteins related to key physiological processes.
- Cost-effective compared to existing solutions.
- Sustainable approach that reduces reliance on antibiotics.